ER positive + HER-2 negative

P=N/A, N=2200, Active, not recruiting, Spotlight Medical

Response to NACT is strongly influenced by ER expression, tumor grade, and sTIL levels. Composite profiles combining these factors can help identify patients most likely to achieve meaningful response, while also highlighting subgroups with low benefit where alternative treatment strategies may be more appropriate.

Intraoperative reirradiation as part of a second BCS (one-day treatment) is feasible, safe, and well-tolerated in selected patients with late local breast cancer recurrence (i.e. < 2 cm. estrogen receptor-positive and node-negative). These findings suggests that shared decision-making between 'one-day treatment' and salvage mastectomy is a safe and viable option.

This represents the largest transcriptomic dataset for ILC from a clinical trial with central histology review. Findings may provide insights to refine treatment and relapse risk assessment for ILC patients.

P2, N=57, Active, not recruiting, Royal Marsden NHS Foundation Trust | Recruiting --> Active, not recruiting | N=324 --> 57 | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Jun 2027

P1, N=33, Recruiting, Halda Therapeutics OpCo, Inc.

P3, N=293, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed

Chemotherapy provides a clear survival benefit in high-risk RS groups, including node-negative patients, whereas intermediate-risk groups show limited benefit. These findings support selective use of CET guided by genomic risk stratification.

Tumor sequencing confirmed both germline variants but showed microsatellite stability and no loss of heterozygosity, arguing against a causal role of MSH6. This case illustrates how PRS, in combination with moderate-risk variants, like those in CHEK2, may drive early-onset MBC and highlights the need to incorporate polygenic models into risk assessment and counseling.

Within an ER+/HER2- BC cohort, higher parity seems to be associated with a higher prevalence of pure ILC. No association was found between parity and clinicopathological features of ER+/HER2- pure ILC.

Diffuse gastrointestinal involvement by invasive lobular carcinoma is uncommon and may mimic inflammatory, infectious, ischemic, or medication-related conditions, contributing to delayed diagnosis. This case highlights an important diagnostic pitfall and underscores the need to consider metastatic disease in patients with a history of lobular breast carcinoma who present with unexplained gastrointestinal symptoms, even in the absence of radiographically apparent disease.